Výsledky vyhledávání - "I Zeberio-Etxetxipia"

Multidisciplinary consensus on the criteria for fertility preservation in cancer patients

Autor: D Manau-Trullas, L Vázquez, Álvaro Rodríguez-Lescure, Á Rovirosa, I Zeberio-Etxetxipia, J Domingo, Ana Santaballa, M Andrés, C Márquez-Vega, L Bassas, E Ceballos-Garcia

Publikováno v: CLINICAL & TRANSLATIONAL ONCOLOGY
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
r-FISABIO. Repositorio Institucional de Producción Científica
Clinical & Translational Oncology
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau

Infertility is one of the main sequelae of cancer and its treatment in both children and adults of reproductive age. It is, therefore, essential that oncologists and haematologists provide adequate information about the risk of infertility and the po

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a63761838d75fb85f6058985c97c0767
https://doi.org/10.1007/s12094-021-02699-2

Zobrazit plný text záznamu

STEM CELL MOBILIZATION AFTER TREATMENT WITH BENDAMUSTINE IN PATIENTS WITH HODGKIN AND B‐CELL NON‐HODGKIN LYMPHOMAS. RESULTS AT DONOSTIA UNIVERSITY HOSPITAL, SPAIN

Autor: A. Arambarri Oyarzabal, N. F. Rois Pego, A. Altuna Mongelos, A. Zumalde Murua, J. J. Ferreiro Martinez, I. Zeberio Etxetxipia, J. Iriondo Alzola, B. Mendibil Esquisabel, A. Alkorta Eizagirre

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::24f1310484013ac0e7ab42f834cbe365
https://doi.org/10.1002/hon.100_2881

Zobrazit plný text záznamu

UPDATED RESULTS OF A PHASE 2 STUDY FROM GELTAMO INVESTIGATING THE COMBINATION OF IBRUTINIB WITH R‐GEMOX IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA

Autor: R. Andreu, B. Rey Búa, Eva Giné, J. J. Sánchez Blanco, F. de la Cruz, A. Martín García-Sancho, I. Zeberio Etxetxipia, Án. Ramírez‐Páyer, MJ Peñarrubia, Arantxa Gutiérrez, C. Grande, Santiago Montes-Moreno, Miguel Ángel Ramírez, Pau Abrisqueta, M. D. Caballero Barrigón, Ana Jiménez-Ubieto, Maria Cruz Viguria, A. De la Fuente, M. José Terol

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::25479ffd5c65af4c92a1bed0d7eba84d
https://doi.org/10.1002/hon.94_2880

Zobrazit plný text záznamu

BRENTUXIMAB VEDOTIN PLUS BENDAMUSTINE AS FIRST SALVAGE TREATMENT IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. EXPERIENCE AT DONOSTIA UNIVERSITY HOSPITAL, SPAIN

Autor: A. Arambarri Oyarzabal, J. Iriondo Alzola, I. Zeberio Etxetxipia, B. Mendibil Esquisabel, L. Ondarra Segurola, A. Zumalde Murua, A. Altuna Mongelos, N. F. Rois Pego

Publikováno v: Hematological Oncology. 39

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::374d48140b3f02b4b5f98d968d8f515d
https://doi.org/10.1002/hon.66_2881

Zobrazit plný text záznamu

ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Autor: Beatriz Rey Búa, A Martín García-Sancho, Eva Giné, M. J. Terol, Rafael Andreu, J. J. Sánchez Blanco, I. Zeberio Etxetxipia, María José Ramírez, Maria Cruz Viguria, Pau Abrisqueta, F de la Cruz, A Ramírez Páyez, A Jiménez Ubieto, MJ Peñarrubia, Caballero Barrigón, Arantxa Gutiérrez, C. Grande, A. De la Fuente

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S381

Context In the present phase II clinical trial (NCT02692248), we investigated the efficacy and toxicity of the combination of ibrutinib with R-GEMOX-D in patients with non-germinal center B-cell like (non-GCB) diffuse large B-cell lymphoma (DLBCL). O

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::7650d625dabe52acbf911399ce1b4cca
https://doi.org/10.1016/s2152-2650(21)01868-1

Zobrazit plný text záznamu

Poster: ABCL-181: Updated Results of a Phase 2 Study from GELTAMO Investigating the Combination of Ibrutinib with R-GEMOX in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Autor: Beatriz Rey Búa, A Jiménez Ubieto, JJ Sánchez Blanco, P Abrisqueta, A Gutiérrez, A Ramírez Páyez, E Giné, I Zeberio Etxetxipia, MJ Terol, F de la Cruz, R Andreu, MJ Ramirez, A de la Fuente, MC Viguria, MJ Peñarrubia, C Grande, MD Caballero Barrigón, A Martín García-Sancho

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 21:S239

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d1a1ef42751714d6b780b977a6623f9
https://doi.org/10.1016/s2152-2650(21)01500-7

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Akademický článek

Ibrutinib in Combination with R-GemOx in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma of Nongerminal Center B-cell-like Type: Phase II Clinical Trial of the Spanish GELTAMO Group.

Autor: Rey-Búa B; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain., Grande C; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Sánchez Blanco JJ; Hematology Department, Hospital General Universitario Morales Meseguer, Murcia, Spain., Abrisqueta P; Hematology Department, Hospital Universitario Vall d'Hebron, Barcelona, Spain., Gutiérrez A; Hematology Department, Hospital Universitario Son Espases, IdISBa, Palma de Mallorca, Spain., Ramírez Páyer Á; Hematology Department, Hospital Universitario Central de Asturias, Asturias, Spain., Giné E; Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Zeberio Etxetxipia I; Hematology Department, Hospital de Donostia, Donostia, Spain., Terol MJ; Hematology Department, Hospital Clínico Valencia, INCLIVA, University of Valencia, Valencia, Spain., de la Cruz Vicente F; Hematology Department, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS)/CSIC/Universidad de Sevilla, Spain., Andreu R; Hematology Department, Hospital Universitario y Politécnico la Fe, Valencia, Spain., Ramirez MJ; Hematology Department, Hospital Especialidades Jerez de la Frontera, Jerez, Spain., de la Fuente A; Hematology Department, Hospital MD Anderson CC, Madrid, Spain., Viguria MC; Hematology Department, Complejo Hospitalario de Navarra, Spain., Peñarrubia MJ; Hematology Department, Hospital Clínico de Valladolid, Valladolid, Spain., Jiménez-Ubieto A; Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Spain., Montes-Moreno S; Anatomic Pathology Department, Translational Hematopathology Lab, IDIVAL/UNICAN, Santander, Spain., López-Guillermo A; Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain., Caballero MD; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.; Medicine Department, University of Salamanca, Salamanca, Spain., Martín García-Sancho A; Hematology Department, Hospital Clínico Universitario de Salamanca, IBSAL, CIBERONC, Salamanca, Spain.; Medicine Department, University of Salamanca, Salamanca, Spain.

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2024 Sep 03; Vol. 30 (17), pp. 3704-3714.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání